drugset

drugset / Trial / NCT05440045

A Clinical Study of 6MW3211 in Patients With Renal Cancer

NCT05440045 ↗

Phase 2 Unknown 30 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer

Timeline

Start: 2022-09-01
Primary completion: 2024-01-01
Completion: 2024-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAFIMESTOMIG	Monoclonal antibody	30 mg/kg	—

Indications